Abstract

Urinary tract infection (UTI) is the most typical and annoying human infection, and the most common causative agent is bacterial infection, which has high recurrence rates, high virulence, and growing resistance to antibiotics. UTI samples were collected from the patient’s nonresponse to antibiotic treatment, and bacteria were identified by morphological, biochemical, and molecular biosystematics. The isolated Streptomyces geysiriensis native actinomycetes strain obtained from Desert Research Center was grown on a starch nitrate broth medium, and the bio-guided active compound of metabolite was isolated and identified by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and authentic sample. Bacterial isolates were identified as Bacillus cereus Ur-09, Pseudomonas aeruginosa Ur-14, and Escherichia coli Ur-33. Successive polarity solvents of cell-free filtrate of S. geysiriensis extract were tested against UTI-bacterial isolated strains for antimicrobial activity. The ethyl acetate (EA) extract is the most effective against bacteria isolated from the urinary tract, with mean inhibition zones of 21.67, 20.33, and 19.77 mm against B. cereus, P. aeruginosa, and E. coli, respectively. The lowest inhibitory concentration was recorded at 5 μg/ml against B. cereus and E. coli, while it was 10 μg/ml against P. aeruginosa. EA S. geysiriensis extract was used to identify by LC–MS/MS determined a major metabolite with potential antimicrobial activities, encompassing 3,4-dihydroxybenzoic acid. An isolated 3,4-dihydroxybenzoic acid is a promising compound with high antibacterial activity against UTI bacterial isolates and to overcome resistant bacteria. The research findings offer perspectives on finding new natural sources of native active isolated compounds as potential sources for pharmacological uses.

Key words: Streptomyces geysiriensis, urinary tract infection, bacterial isolation, antimicrobial activity, ‎isolated compound, 3,4-dihydroxybenzoic acid